|
DHFRL1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.89603888145484E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.4564573425655E-12 |
| Normal-vs-Stage2 |
1.35540001444667E-09 |
| Normal-vs-Stage3 |
2.26485497023532E-14 |
| Normal-vs-Stage4 |
1.62470037423645E-12 |
| Stage1-vs-Stage2 |
8.075600E-01 |
| Stage1-vs-Stage3 |
2.650000E-02 |
| Stage1-vs-Stage4 |
5.82419999999306E-05 |
| Stage2-vs-Stage3 |
8.675700E-02 |
| Stage2-vs-Stage4 |
1.780450E-03 |
| Stage3-vs-Stage4 |
6.787600E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.69753100465186E-12 |
| Normal-vs-AfricanAmerican |
9.4024999997E-07 |
| Normal-vs-Asian |
2.91530022344944E-10 |
| Caucasian-vs-AfricanAmerican |
4.353200E-01 |
| Caucasian-vs-Asian |
3.306600E-01 |
| AfricanAmerican-vs-Asian |
9.625800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.10227407598995E-13 |
| Normal-vs-Female |
3.44835271448574E-13 |
| Male-vs-Female |
7.852600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.57696119787943E-13 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.31117339208231E-13 |
| Normal-vs-Age(81-100Yrs) |
9.59499999999558E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.641200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.887000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.351200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.824400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.593200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.554400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.777100E-03 |
| Classical-VS-Follicular |
3.512800E-01 |
| Classical-VS-Other |
7.520000E-01 |
| Classical-VS-Normal |
7.0716765776524E-12 |
| Tall-VS-Follicular |
5.563500E-04 |
| Tall-VS-Other |
4.213200E-01 |
| Tall-VS-Normal |
6.55031584528842E-15 |
| Follicular-VS-Other |
5.861800E-01 |
| Follicular-VS-Normal |
9.1069041197045E-11 |
| Other-VS-Normal |
1.559560E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
1.62481139653892E-12 |
| N0-vs-N1 |
6.424600E-04 |
|
|
